《胸部恶性肿瘤围术期静脉血栓栓塞症预防中国专家共识（2018版）》解读之直接口服抗凝药应用前瞻篇

Venous thromboembolism (VTE) is a preventable perioperative complication of malignant tumor in thoracic surgery. At present, low molecular weight heparin anticoagulants are the first choices for perioperative drug prevention of malignant tumors, and direct oral anticoagulants are not recommended for...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
专家视点
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935040/
https://www.ncbi.nlm.nih.gov/pubmed/31874670
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.12.04
Descripción
Sumario:Venous thromboembolism (VTE) is a preventable perioperative complication of malignant tumor in thoracic surgery. At present, low molecular weight heparin anticoagulants are the first choices for perioperative drug prevention of malignant tumors, and direct oral anticoagulants are not recommended for perioperative use of malignant tumors in thoracic surgery, but their application in other related fields is relatively mature. This article will introduce direct oral anticoagulants and analyze the prospect of their perioperative application in patients with thoracic malignant tumors. It is helpful to better understand the relevant contents of "perioperative VTE prophylaxis in thoracic cancer patients: Chinese experts consensus (2018 edition)".

Ejemplares similares